HIV treatment cascade in tuberculosis patients

Richard J Lessells, Soumya Swaminathan, Peter Godfrey-Faussett, Richard J Lessells, Soumya Swaminathan, Peter Godfrey-Faussett

Abstract

Purpose of review: Globally, the number of deaths associated with tuberculosis (TB) and HIV coinfection remains unacceptably high. We review the evidence around the impact of strengthening the HIV treatment cascade in TB patients and explore recent findings about how best to deliver integrated TB/HIV services.

Recent findings: There is clear evidence that the timely provision of antiretroviral therapy (ART) reduces mortality in TB/HIV coinfected adults. Despite this, globally in 2013, only around a third of known HIV-positive TB cases were treated with ART. Although there is some recent evidence exploring the barriers to achieve high coverage of HIV testing and ART initiation in TB patients, our understanding of which factors are most important and how best to address these within different health systems remains incomplete. There are some examples of good practice in the delivery of integrated TB/HIV services to improve the HIV treatment cascade. However, evidence of the impact of such strategies is of relatively low quality for informing integrated TB/HIV programming more broadly. In most settings, there remain barriers to higher-level organizational and functional integration.

Summary: There remains a need for commitment to patient-centred integrated TB/HIV care in countries affected by the dual epidemic. There is a need for better quality evidence around how best to deliver integrated services to strengthen the HIV treatment cascade in TB patients, both at primary healthcare level and within community settings.

Figures

FIGURE 1
FIGURE 1
HIV treatment cascade in TB patients and indicators used to evaluate the cascade.
FIGURE 2
FIGURE 2
Cascade graph of diagnosis and treatment of HIV in TB cases, 2013 (global data) [1].
Box 1
Box 1
no caption available

References

    1. World Health Organization. Global tuberculosis report 2014. Geneva, Switzerland: World Health Organization; 2014.
    1. World Health Organization. Gear up to end TB: introducing the end TB strategy. Geneva, Switzerland: World Health Organization; 2015.
    1. World Health Organization. Global update on HIV treatment 2013: results, impact and opportunities: WHO report in partnership with UNICEF and UNAIDS. Geneva, Switzerland: World Health Organization; 2013.
    1. World Health Organization. Metrics for monitoring the cascade of HIV testing, care and treatment services in Asia and the Pacific. Geneva, Switzerland: World Health Organization; 2014.
    1. World Health Organization. WHO policy on collaborative TB/HIV activities: guidelines for national programmes and other stakeholders. Geneva, Switzerland: World Health Organization; 2012.
    1. Gupta S, Granich R, Date A, et al. Review of policy and status of implementation of collaborative HIV-TB activities in 23 high-burden countries. Int J Tuberc Lung Dis 2014; 18:1149–1158.
    1. Herbert N, George A, Baroness Masham of Ilton, et al. World TB Day 2014: finding the missing 3 million. Lancet 2014; 383:1016–1018.
    1. Trinh QM, Nguyen HL, Nguyen VN, et al. Tuberculosis and HIV co-infection-focus on the Asia-Pacific region. Int J Infect Dis 2015; 32:170–178.
    1. Kaplan R, Caldwell J, Bekker LG, et al. Integration of TB and ART services fails to improve TB treatment outcomes: comparison of ART/TB primary healthcare services in Cape Town, South Africa. S Afr Med J 2014; 104:204–209.
    1. Loveday M, Wallengren K, Brust J, et al. Community-based care vs. centralised hospitalisation for MDR-TB patients, KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis 2015; 19:163–171.
    1. Gupta AK, Singh GP, Goel S, et al. Efficacy of a new model for delivering integrated TB and HIV services for people living with HIV/AIDS in Delhi: case for a paradigm shift in national HIV/TB cross-referral strategy. AIDS Care 2014; 26:137–141.

    2. This study from Delhi highlights the importance of colocation of services to limit fragmentation of care.

    1. World Health Organization. Scaling up of collaborative TB/HIV activities in concentrated HIV epidemic settings: a case study from India. Geneva, Switzerland: World Health Organization; 2015.

    2. An excellent and comprehensive report detailing successes and challenges of scaling up collaborative TB/HIV activities in India.

    1. Kumar AM, Gupta D, Gupta RS, et al. HIV testing in people with presumptive tuberculosis: time for implementation. Lancet Respir Med 2013; 1:7–9.
    1. Smith J, Moyo S, Day C. A review of TB in children and adolescents in South Africa 2008–2012. In South African Health Review 2013/14. Padarath A, English R, eds. Durban: Health Systems Trust; 2014.
    1. Kebede W, Keno F, Ewunetu T, Mamo G. Acceptance of provider initiated HIV testing and counseling among tuberculosis patients in East Wollega Administrative Zone, Oromia Regional State, Western Ethiopia. Tuberc Res Treat 2014; 2014:935713.

    2. This study demonstrated high uptake of HIV testing and suggested that uptake was associated with general knowledge of HIV and individual perception of HIV risk.

    1. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach – 2010 revision. Geneva, Switzerland: WHO; 2010.
    1. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach June 2013. Geneva, Switzerland: WHO; 2013.
    1. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362:697–706.
    1. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011; 365:1492–1501.
    1. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011; 365:1471–1481.
    1. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011; 365:1482–1491.
    1. Odone A, Amadasi S, White RG, et al. The impact of antiretroviral therapy on mortality in HIV positive people during tuberculosis treatment: a systematic review and meta-analysis. PLoS One 2014; 9:e112017.

    2. A meta-analysis of predominantly observational studies that highlights the impact of early ART initiation on mortality.

    1. Padayatchi N, Abdool Karim SS, Naidoo K, et al. Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial. Int J Tuberc Lung Dis 2014; 18:147–154.

    2. This study from South Africa highlights the importance of early ART for survival in multidrug-resistant TB.

    1. Pietersen E, Ignatius E, Streicher EM, et al. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet 2014; 383:1230–1239.

    2. This study also from South Africa demonstrates that ART is associated with reduced mortality in extensively drug-resistant TB.

    1. Kaplan R, Caldwell J, Middelkoop K, et al. Impact of ART on TB case fatality stratified by CD4 count for HIV-positive TB patients in Cape Town, South Africa (2009-2011). J Acquir Immune Defic Syndr 2014; 66:487–494.

    2. This study demonstrates increasing ART uptake in Cape Town over a 3-year period and a modest reduction in mortality over the same period. The findings also highlight that the mortality is largely driven by those with lower CD4+ cell counts and that gaps still exist in getting these cases onto ART.

    1. Mfinanga SG, Kirenga BJ, Chanda DM, et al. Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial. Lancet Infect Dis 2014; 14:563–571.

    2. A multicentre RCT in Africa suggesting that there is no clear benefit from early ART initiation in those with less-advanced immunodeficiency. Although the evidence may not change policy, it does highlight that people with low CD4+ cell counts remain the priority for early initiation of ART.

    1. Yan S, Chen L, Wu W, et al. Early versus delayed antiretroviral therapy for HIV and tuberculosis co-infected patients: a systematic review and meta-analysis of randomized controlled trials. PLoS One 2015; 10:e0127645.
    1. Marcy O, Laureillard D, Madec Y, et al. Causes and determinants of mortality in HIV-infected adults with tuberculosis: an analysis from the CAMELIA ANRS 1295-CIPRA KH001 randomized trial. Clin Infect Dis 2014; 59:435–445.

    2. A post-hoc analysis from one of the RCTs exploring early ART initiation during TB treatment. The findings highlight the long-term protective effect of ART started early during TB treatment.

    1. Amogne W, Aderaye G, Habtewold A, et al. Efficacy and safety of antiretroviral therapy initiated one week after tuberculosis therapy in patients with CD4 counts < 200 cells/μL: TB-HAART study, a randomized clinical trial. PLoS One 2015; 10:e0122587.
    1. Suthar AB, Rutherford GW, Horvath T, et al. Improving antiretroviral therapy scale-up and effectiveness through service integration and decentralization. AIDS 2014; 28 Suppl 2:S175–S185.
    1. Van Rie A, Patel MR, Nana M, et al. Integration and task shifting for TB/HIV care and treatment in highly resource-scarce settings: one size may not fit all. J Acquir Immune Defic Syndr 2014; 65:e110–e117.

    2. Main findings from the ITART study in the Democratic Republic of Congo demonstrating that integrated, nurse-delivered TB/HIV care improved uptake of ART and reduced mortality in comparison to a historical cohort.

    1. Patel MR, Nana M, Yotebieng M, et al. Delayed antiretroviral therapy despite integrated treatment for tuberculosis and HIV infection. Int J Tuberc Lung Dis 2014; 18:694–699.

    2. Analysis of data from the ITART study, highlighting persistent delays in initiation of ART and some of the factors contributing to that delay.

    1. Patel MR, Westreich D, Yotebieng M, et al. The impact of implementation fidelity on mortality under a CD4+ stratified timing strategy for antiretroviral therapy in patients with tuberculosis. Am J Epidemiol 2015; 181:714–722.

    2. Analysis of data from the ITART study, highlighting the potential to save lives by more timely initiation of ART.

    1. Ikeda JM, Tellez CA, Hudes ES, et al. Impact of integrating HIV and TB care and treatment in a regional tuberculosis hospital in rural Guatemala. AIDS Behav 2014; 18 Suppl 1:S96–S103.
    1. Owiti P, Zachariah R, Bissell K, et al. Integrating tuberculosis and HIV services in rural Kenya: uptake and outcomes. Public Health Action 2015; 5:36–44.
    1. Tweya H, Ben-Smith A, Kalulu M, et al. Timing of antiretroviral therapy and regimen for HIV-infected patients with tuberculosis: the effect of revised HIV guidelines in Malawi. BMC Public Health 2014; 14:183.

    2. This study demonstrates that implementing guideline changes can lead to improvements in ART uptake but that these improvements may be modest and so achieving high levels of uptake may require more targeted intervention.

    1. Kebogile M, Elias P. Why do patients refuse antiretroviral therapy before they complete tuberculosis treatment?. A qualitative enquiry. J AIDS HIV Res 2014; 6:33–38.

    2. This study explores why some people choose to defer ART and highlights areas that could be addressed in education and counselling.

    1. Seeling S, Mavhunga F, Thomas A, et al. Barriers to access to antiretroviral treatment for HIV-positive tuberculosis patients in Windhoek, Namibia. Int J Mycobacteriol 2014; 3:268–275.
    1. Wajanga BM, Peck RN, Kalluvya S, et al. Healthcare worker perceived barriers to early initiation of antiretroviral and tuberculosis therapy among Tanzanian inpatients. PLoS One 2014; 9:e87584.
    1. Patel MR, Yotebieng M, Behets F, et al. Outcomes of integrated treatment for tuberculosis and HIV in children at the primary healthcare level. Int J Tuberc Lung Dis 2013; 17:1206–1211.
    1. Soeters HM, Napravnik S, Patel MR, et al. The effect of tuberculosis treatment on virologic and CD4+ cell count response to combination antiretroviral therapy: a systematic review. AIDS 2014; 28:245–255.

    2. This systematic review suggests that virological response to first-line ART is not affected by TB treatment.

    1. Reepalu A, Balcha TT, Skogmar S, et al. High rates of virological suppression in a cohort of human immunodeficiency virus-positive adults receiving antiretroviral therapy in Ethiopian health centers irrespective of concomitant tuberculosis. Open Forum Infect Dis 2014; 1:ofu039.
    1. Jiang HY, Zhang MN, Chen HJ, et al. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis. Int J Infect Dis 2014; 25:130–135.
    1. Soeters HM, Sawry S, Moultrie H, Rie AV. The effect of tuberculosis treatment on virologic and immunologic response to combination antiretroviral therapy among South African children. J Acquir Immune Defic Syndr 2014; 67:136–144.

    2. One of the very few articles focused on paediatric TB/HIV, providing reassurance that even in children virological outcomes do not seem to be adversely affected by TB treatment.

    1. Uyei J, Coetzee D, Macinko J, et al. Measuring the degree of integrated tuberculosis and HIV service delivery in Cape Town, South Africa. Health Policy Plan 2014; 29:42–55.

    2. This article describes an attempt to measure integration, taking into account various aspects of healthcare delivery and organization.

    1. Uyei J, Coetzee D, Macinko J, et al. The influence of integrated tuberculosis and human immunodeficiency virus service delivery on patient outcomes. Int J Tuberc Lung Dis 2014; 18:315–321.

    2. This follows on from the previous article in applying the tool measuring integration to an analysis of individual patient outcomes. The results suggest that higher levels of integration do impact on patient outcomes, although the results were not consistent across all domains of integration.

    1. Kufa T, Hippner P, Charalambous S, et al. A cluster randomised trial to evaluate the effect of optimising TB/HIV integration on patient level outcomes: the “merge” trial protocol. Contemp Clin Trials 2014; 39:280–287.
    1. Columbia University. Start TB patients on ART and retain on treatment (START study), vol. 2015. Bethesda, MD: National Library of Medicine (US).
    1. Frasca K, Cohn J. Integration of HIV and tuberculosis in the community. J Int Assoc Provid AIDS Care 2014; 13:534–538.
    1. Gilbert JA, Long EF, Brooks RP, et al. Integrating community-based interventions to reverse the convergent TB/HIV epidemics in rural South Africa. PLoS One 2015; 10:e0126267.

    2. Results from mathematical modelling which emphasize the potential impact of moving TB and HIV interventions into the community in a particularly high-burden district of South Africa.

    1. Arshad A, Salam RA, Lassi ZS, et al. Community based interventions for the prevention and control of tuberculosis. Infect Dis Poverty 2014; 3:27.
    1. Department of Health RoSA. Joint review of HIV, TB and PMTCT programmes in South Africa. Pretoria, South Africa: Department of Health RoSA; 2014.

    2. A comprehensive independent evaluation of the national HIV and TB programmes in South Africa, which provides rich detail and context, particularly around challenges to HIV/TB integration.

    1. Amo-Adjei J, Kumi-Kyereme A, Fosuah Amo H, Awusabo-Asare K. The politics of tuberculosis and HIV service integration in Ghana. Soc Sci Med 2014; 117:42–49.

    2. Another interesting discursive article, pointing out some of the structural and functional barriers toTB/HIV integration.

    1. Daftary A, Calzavara L, Padayatchi N. The contrasting cultures of HIV and tuberculosis care. AIDS 2015; 29:1–4.
    1. Global Fund Interagency Working Group on TB/HIV. Joint tuberculosis and HIV programming information note. Geneva, Switzerland: Global Fund Interagency Working Group on TB/HIV; 2014.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi